Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes

Summary Type 2 diabetes (T2D) is a major comorbidity of COVID-19. However, the impact of blood glucose (BG) control on the degree of required medical interventions and on mortality in patients with COVID-19 and T2D remains uncertain. Thus, we performed a retrospective, multi-centered study of 7,337 cases of COVID-19 in Hubei Province, China, among which 952 had pre-existing T2D. We found that subjects with T2D required more medical interventions and had a significantly higher mortality (7.8% versus 2.7%; adjusted hazard ratio [HR], 1.49) and multiple organ injury than the non-diabetic individuals. Further, we found that well-controlled BG (glycemic variability within 3.9 to 10.0 mmol/L) was associated with markedly lower mortality compared to individuals with poorly controlled BG (upper limit of glycemic variability exceeding 10.0 mmol/L) (adjusted HR, 0.14) during hospitalization. These findings provide clinical evidence correlating improved glycemic control with better outcomes in patients with COVID-19 and pre-existing T2D.

[1]  A. Sinclair,et al.  Mean HbA1c, HbA1c variability, and mortality in people with diabetes aged 70 years and older: a retrospective cohort study. , 2018, The lancet. Diabetes & endocrinology.

[2]  Gary King,et al.  Matching as Nonparametric Preprocessing for Reducing Model Dependence in Parametric Causal Inference , 2007, Political Analysis.

[3]  M. Frieman,et al.  Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. , 2019, JCI insight.

[4]  E. Holmes,et al.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.

[5]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[6]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[7]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[8]  Elizabeth Rea,et al.  Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. , 2003, JAMA.

[9]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[10]  J. Thachil,et al.  Differentiating disseminated intravascular coagulation (DIC) with the fibrinolytic phenotype from coagulopathy of trauma and acute coagulopathy of trauma‐shock (COT/ACOTS) , 2013, Journal of thrombosis and haemostasis : JTH.

[11]  R. McCoy,et al.  Benefits and harms of intensive glycemic control in patients with type 2 diabetes , 2019, BMJ.

[12]  Sheng-Qun Deng,et al.  Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China , 2020, Journal of clinical medicine.

[13]  Mark Chappell,et al.  A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury , 2005, Nature Medicine.

[14]  J. Marrero,et al.  Comparison of imputation methods for missing laboratory data in medicine , 2013, BMJ Open.

[15]  Tariq M. Alhawassi,et al.  Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective study , 2018, Epidemiology and Infection.

[16]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[17]  Geltrude Mingrone,et al.  Practical recommendations for the management of diabetes in patients with COVID-19 , 2020, The Lancet Diabetes & Endocrinology.

[18]  P. Grambsch,et al.  Penalized Survival Models and Frailty , 2003 .

[19]  B. Philips,et al.  appearance of glucose in upper and lower respiratory tract secretions , 2003 .

[20]  Yichong Li,et al.  Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013 , 2017, JAMA.

[21]  Jasjeet S. Sekhon,et al.  Multivariate and Propensity Score Matching Software with Automated Balance Optimization: The Matching Package for R , 2008 .

[22]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[23]  Hongliang Li,et al.  Innate Immune Signaling and Its Role in Metabolic and Cardiovascular Diseases. , 2019, Physiological reviews.

[24]  G. Van den Berghe,et al.  Intensive insulin therapy in the medical ICU. , 2006, The New England journal of medicine.

[25]  S. Babu,et al.  Influence of diabetes mellitus on immunity to human tuberculosis , 2017, Immunology.

[26]  Maya B. Mathur,et al.  Web Site and R Package for Computing E-values. , 2018, Epidemiology.

[27]  Norbert Lameire,et al.  Notice , 2012, Kidney International Supplements.

[28]  Tyler J. VanderWeele,et al.  Using the E-Value to Assess the Potential Effect of Unmeasured Confounding in Observational Studies , 2019, JAMA.

[29]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[30]  Qingbo Xu,et al.  Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19 , 2020, Circulation research.

[31]  J. Chan,et al.  Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[32]  R. Antonelli-Incalzi,et al.  Diabetic lung, an underrated complication from restrictive functional pattern to pulmonary hypertension , 2019, Diabetes/metabolism research and reviews.

[33]  M. Cooper,et al.  Prevention of Accelerated Atherosclerosis by Angiotensin-Converting Enzyme Inhibition in Diabetic Apolipoprotein E–Deficient Mice , 2002, Circulation.

[34]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[35]  C. Akdis,et al.  Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China , 2020, Allergy.

[36]  A. Gasbarrini,et al.  Drug-induced liver injury 2017: the diagnosis is not easy but always to keep in mind. , 2017, European review for medical and pharmacological sciences.

[37]  Tyler J. VanderWeele,et al.  Sensitivity Analysis in Observational Research: Introducing the E-Value , 2017, Annals of Internal Medicine.